Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline receives European approval for Benlysta

GlaxoSmithKline receives European approval for Benlysta

15th July 2011

GlaxoSmithKline has been granted approval from the European Commission for Benlysta, its new treatment for systemic lupus erythematosus (SLE).

In association with partner Human Genome Sciences, the company has won authorisation for the drug to be marketed as an add-on therapy in adult patients with active autoantibody-positive SLE.

This comes after the treatment was approved in the same indication in the US and Canada earlier this year, with further regulatory reviews currently taking place worldwide.

Dr Tony Hoos, senior vice-president for European medical affairs at GlaxoSmithKline, said this latest approval represents a "significant milestone".

He added: "We are very pleased to be able to provide physicians an additional therapeutic option for treating appropriate patients with this chronic disease."

Earlier this month, the company submitted an application for Votrient to be approved as an advanced soft tissue sarcoma in the EU and US.ADNFCR-8000103-ID-800622983-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.